4.4 Review

Subtype-selective conopeptides targeted to nicotinic receptors - Concerted discovery and biomedical applications

期刊

CHANNELS
卷 2, 期 2, 页码 143-152

出版社

TAYLOR & FRANCIS INC
DOI: 10.4161/chan.2.2.6276

关键词

Conus; discovery; nicotinic; Parkinson's disease; pain; inflammation

资金

  1. NIH [GM 48677, NS 42091, NS47162, NS 48158, MH 53631, DA12242]
  2. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053631, R29MH053631] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042091, R01NS048158, R01NS047162] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012242] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Conus peptides that are selectively targeted to different molecular isoforms of nicotinic acetylcholine receptors (nAChRs) have been identified and characterized; several have recently been shown to have significant biomedical potential. An emerging strategy for the discovery from animal biodiversity of subtype-specific ligands for ion channel families is described in this review. Characterization of the gene family encoding a set of related ligands is required for discovery using a molecular genetics approach; when discovery is guided by a knowledge of the phylogeny of the biodiverse animal lineage being used as a source of ligands, a rational, efficient scan of the library of putative ligands becomes feasible. Together, these constitute an approach to uncover subtype-specific ligands, called concerted discovery; this was applied to the alpha-conotoxins, a family of Conus peptides generally targeted to nAChRs. Subtype-specific alpha-conotoxins were developed that target two groups of nAChRs, a(6)* and a(9)*. alpha-conotoxin MII has become the defining ligand for identifying the a6* nAChR subtype. A synthetic analog, MII [E11A], further subdivides a6* nAChRs into those that contain an alpha(4) subunit and those that do not. Importantly, these two subtypes are differentially affected by nigrostriatal damage, findings of likely relevance to the pathopysiology of Parkinson's disease. In contrast, alpha-conotoxins that target alpha(9) nAChR subtypes have potential as analgesics for the treatment of neuropathic pain that develops after nerve injury. The discovery of alpha-conotoxin RgIA enabled the identification of a novel role for alpha(9)* nAChRs. Use of alpha(9)* nAChR antagonists is associated with reversal of inflammation caused by the nerve injury. Thus, subtype-specific alpha-conotoxins targeted to particular nAChR isoforms are not only useful for understanding the physiological role of these receptors, but can have important diagnostic and therapeutic applications as well.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据